Drug intelligence / Profile preview

BIO017

Development stage: Unknown
Lead developer: Biom Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

BIO017 is a plant-derived, water-soluble cannabidiol (CBD) formulation developed by Biom Therapeutics as a small molecule agonist of the TRPV1 channel. It is specifically designed to treat neurodevelopmental and epileptic disorders, including Angelman Syndrome and Developmental and Epileptic Encephalopathies (DEE), by modulating TRPV1-mediated neuronal activity. The drug utilizes a patent-pending nano-dispersion technology to enhance solubility and is formulated as a sugar-free, child-friendly oral treatment. BIO017 has received Orphan Drug Designation from the FDA for Angelman Syndrome and is currently undergoing Phase 1 clinical evaluation in the SATURN trial, with plans to progress to Phase 3.

Other names: water-soluble cannabidiol

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on BIO017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO017.

Explore the full profile